Does semaglutide reduce the incidence of atrial fibrillation in individuals at high cardiovascular risk?
Semaglutide reduces the incidence of atrial fibrillation by 42% in high cardiovascular risk patients, regardless of administration route, diabetes status, or BMI.
Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.
Saglietto et al. (2024) studied this question.